Crohn's Disease

Immunology
115
Pipeline Programs
27
Companies
50
Clinical Trials
2 recruiting
19
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
4
28
3
43
29
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2368%
Small Molecule
721%
RNA Therapeutic
26%
Cell Therapy
13%
Peptide
13%
+ 91 programs with unclassified modality

On Market (19)

Approved therapies currently available

UP
CIMZIAApproved
certolizumab pegol
UCB Pharma
Tumor Necrosis Factor Blocker [EPC]injection2008
U
CORTANApproved
prednisone
Unknown Company
oral
U
DEXAMETHASONEApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]oral1971
U
DEXONE 0.5Approved
dexamethasone
Unknown Company
oral
U
DEXONE 0.75Approved
dexamethasone
Unknown Company
oral
U
DEXONE 1.5Approved
dexamethasone
Unknown Company
oral1975
U
DEXONE 4Approved
dexamethasone
Unknown Company
oral
U
DEXYCU KITApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]intraocular2018
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
U
LIQUID PREDApproved
prednisone
Unknown Company
oral1982
U
MAXIDEXApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]ophthalmic1962
U
ORASONEApproved
prednisone
Unknown Company
oral1974
Bristol Myers Squibb
ORENCIAApproved
abatacept
Bristol Myers Squibb
Selective T Cell Costimulation Modulator [EPC]iv (infusion)2005
U
PREDNICEN-MApproved
prednisone
Unknown Company
oral1975
U
REMICADEApproved
infliximab
Unknown Company
Tumor Necrosis Factor Blocker [EPC]intravenous1998
AbbVie
RINVOQApproved
upadacitinib
AbbVie
Janus Kinase Inhibitor [EPC]oral2019
AbbVie
RINVOQ LQApproved
upadacitinib
AbbVie
Janus Kinase Inhibitor [EPC]oral2024
Biogen
TYSABRIApproved
natalizumab
Biogen
Integrin Receptor Antagonist [EPC]single-use2004
U
UPADACITINIBApproved
upadacitinib
Unknown Company
oral

Competitive Landscape

26 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
27 programs
6
13
3
Certolizumab PegolPhase 41 trial
CimziaPhase 41 trial
certolizumab pegolPhase 41 trial
Certolizumab PegolPhase 31 trial
Certolizumab PegolPhase 31 trial
+22 more programs
Active Trials
NCT03559660No Longer Available
NCT00844285Completed3,072Est. Aug 2020
NCT00496548Completed159Est. Dec 2015
+24 more trials
Takeda
TakedaTOKYO, Japan
13 programs
1
5
3
2
CDPATH™Phase 41 trial
PrednisonePhase 41 trial
Cx601Phase 34 trials
OntamalimabPhase 3Monoclonal Antibody1 trial
Vedolizumab IVPhase 31 trial
+8 more programs
Active Trials
NCT04971525Withdrawn0Est. Dec 2027
NCT05113095Recruiting275Est. Dec 2029
NCT04701411Terminated7Est. May 2025
+21 more trials
Abbott
AbbottABBOTT PARK, IL
10 programs
1
1
1
1
Treatment Algorithm for Crohn's DiseasePhase 41 trial
AdalimumabPhase 3Monoclonal Antibody1 trial
adalimumabPhase 2/3Monoclonal Antibody1 trial
AdalimumabPhase 2Monoclonal Antibody1 trial
Adalimumab and InfliximabN/AMonoclonal Antibody1 trial
+5 more programs
Active Trials
NCT01338740Completed21Est. Feb 2014
NCT01074580Terminated20Est. Dec 2013
NCT01083680Completed4,107Est. Dec 2015
+7 more trials
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
8 programs
1
3
1
1
Crohn's DiseasePhase 41 trial
MesalazinePhase 31 trial
SemapimodPhase 21 trial
SemapimodPhase 21 trial
SemapimodPhase 21 trial
+3 more programs
Active Trials
NCT01468090Completed192Est. Jun 2014
NCT02193048Completed216Est. Dec 2021
NCT00950105Completed30Est. Oct 2009
+5 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
8 programs
5
1
AdalimumabPhase 3Monoclonal Antibody
AdalimumabPhase 3Monoclonal Antibody
AdalimumabPhase 3Monoclonal Antibody1 trial
UpadacitinibPhase 3Small Molecule1 trial
adalimumabPhase 3Monoclonal Antibody1 trial
+3 more programs
Active Trials
NCT01674413Withdrawn0Est. Mar 2016
NCT03345849Completed526Est. Jan 2022
NCT02499783Completed205Est. Dec 2017
Biogen
BiogenCAMBRIDGE, MA
7 programs
1
2
2
natalizumabPhase 4Monoclonal Antibody1 trial
natalizumabPhase 4Monoclonal Antibody1 trial
natalizumabPhase 3Monoclonal Antibody1 trial
natalizumabPhase 3Monoclonal Antibody1 trial
natalizumabPhase 2Monoclonal Antibody1 trial
+2 more programs
Active Trials
NCT00472992Completed376Est. Jul 2012
NCT00707512Terminated87Est. May 2015
NCT00055367Completed30Est. May 2004
+4 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
InfliximabPhase 4Monoclonal Antibody1 trial
PF-04236921 SC injectionPhase 21 trial
Active Trials
NCT01287897Completed250Est. Feb 2015
NCT02517684Completed100Est. Jan 2024
Bristol Myers Squibb
1 program
1
1
abataceptPhase 31 trial
Active Trials
NCT00406653Terminated451Est. Nov 2009
M&
Merck & Co.RAHWAY, NJ
6 programs
1
InfliximabPhase 3Monoclonal Antibody5 trials
Blood and stool sampleN/A1 trial
Data collection post infusionN/A1 trial
Disease Course in an IBD Cohort in the Era of Biological TreatmentN/A
Endomicroscopy in IBD PatientsN/A1 trial
+1 more programs
Active Trials
NCT01813500Completed400Est. Apr 2016
NCT00755937Terminated556Est. Sep 2007
NCT01417728Completed50Est. Aug 2013
+6 more trials
Teva
TevaIsrael - Petach Tikva
6 programs
2
3
1
DuvakitugPhase 32 trials
80 mg DR-6MPPhase 21 trial
LaquinimodPhase 21 trial
etiprednol dicloacetatePhase 21 trial
Delayed Release 6 mercaptopurinePhase 1/21 trial
+1 more programs
Active Trials
NCT01094613Terminated70Est. Dec 2012
NCT00287170Completed15Est. Dec 2007
NCT01433432Withdrawn0Est. Aug 2012
+4 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
5 programs
2
1
2
Brazikumab Induction DosePhase 31 trial
D9421-C capsule 3 mgPhase 31 trial
D9421-C, 9mgPhase 21 trial
AMG 139Phase 11 trial
AZD7798Phase 11 trial
Active Trials
NCT01258205Completed48Est. Feb 2015
NCT06053424Completed13Est. Oct 2024
NCT00573469Completed75Est. Mar 2008
+2 more trials
Celltrion
CelltrionKorea - Incheon
4 programs
1
2
CT-P13Phase 3
CT-P13 SCPhase 31 trial
CT-P13Phase 11 trial
To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative N/A1 trial
Active Trials
NCT02326155Terminated470Est. Feb 2020
NCT02883452Completed181Est. Oct 2019
NCT03945019Completed396Est. Aug 2023
GS
Gilead SciencesFOSTER CITY, CA
3 programs
1
2
FilgotinibPhase 3Small Molecule1 trial
FilgotinibPhase 3Small Molecule
AndecaliximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02405442Terminated187Est. Dec 2016
NCT02914561Completed1,372Est. Nov 2022
Galapagos
Galapagos2800 MECHELEN, Belgium
3 programs
1
2
FilgotinibPhase 3Small Molecule
FilgotinibPhase 3Small Molecule
GLPG0634Phase 21 trial
Active Trials
NCT02048618Completed175Est. Feb 2016
Ionis Pharmaceuticals
2 programs
2
AlicaforsenPhase 3RNA Therapeutic1 trial
AlicaforsenPhase 3RNA Therapeutic1 trial
Active Trials
NCT00048113Completed150Est. Apr 2002
NCT00048295Completed150
Tillotts Pharma
Tillotts PharmaSwitzerland - Rheinfelden
2 programs
2
EpanovaPhase 31 trial
Epanova™Phase 31 trial
Active Trials
NCT00613197CompletedEst. Aug 2006
NCT00074542CompletedEst. Jan 2005
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
2
Rifaximin EIRPhase 31 trial
Rifaximin EIRPhase 31 trial
Active Trials
NCT02240121TerminatedEst. Aug 2017
NCT02240108TerminatedEst. Oct 2017
Quince Therapeutics
Quince TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
DexamethasonePhase 31 trial
Active Trials
NCT01277289TerminatedEst. Jun 2012
E
EisaiChina - Liaoning
5 programs
1
1
1
2
adalimumabPhase 2/3Monoclonal Antibody
adalimumabPhase 2/3Monoclonal Antibody
E6011Phase 21 trial
E6011 2 mg/kgPhase 1/21 trial
E6011Phase 11 trial
Active Trials
NCT02249078Withdrawn0Est. Apr 2016
NCT02039063Completed28Est. Nov 2017
NCT03733314Completed25Est. Apr 2024
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
BrodalumabPhase 2Monoclonal Antibody1 trial
CCX282-BPhase 22 trials
Active Trials
NCT01199302Terminated67Est. Oct 2011
NCT00306215Completed436Est. Jun 2009
NCT00102921Completed70Est. Dec 2005
H
HutchmedChina - Hong Kong
1 program
1
HMPL-004Phase 21 trial
Active Trials
NCT00655733Completed101Est. Apr 2009
Celularity
CelularityFLORHAM PARK, NJ
1 program
1
Human Placenta-Derived Cells PDA001 Intravenous InfusionPhase 21 trial
Active Trials
NCT01155362Completed50Est. Apr 2014
Qu Biologics
Qu BiologicsBC - Burnaby
1 program
1
QBECOPhase 1/21 trial
Active Trials
NCT01809275CompletedEst. Jul 2016
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
2
EmpagliflozinPhase 1Small Molecule1 trial
G-CSFPhase 11 trial
Active Trials
NCT05078879CompletedEst. May 2025
NCT00025805CompletedEst. Jun 2008
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
Green teaN/A1 trial
Two-stage nutritional therapy conceptN/A1 trial
Active Trials
NCT01231217Unknown80
NCT06719778Recruiting30Est. Apr 2027
SetPoint Medical
SetPoint MedicalCA - Valencia
1 program
Vagus Nerve Stimulation DeviceN/A1 trial
Active Trials
NCT02311660Unknown15Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaCDPATH™
TakedaDarvadstrocel
TakedaPrednisone
UCB PharmaCertolizumab Pegol
PfizerInfliximab
UCB PharmaCimzia
Merck & Co.Infliximab
AbbottTreatment Algorithm for Crohn's Disease
UCB Pharmacertolizumab pegol
Biogennatalizumab
Merck & Co.Infliximab
Merck & Co.Infliximab
Merck & Co.Infliximab
Ferring PharmaceuticalsCrohn's Disease
Merck & Co.Infliximab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 16,596 patients across 50 trials

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Start: Jun 2021Est. completion: Sep 2026200 patients
Phase 4Active Not Recruiting
NCT04118088TakedaDarvadstrocel

A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Start: Dec 2020Est. completion: Feb 202553 patients
Phase 4Terminated

Corticosteroids With Vedolizumab in Crohn's Disease

Start: Apr 2016Est. completion: Feb 20181 patients
Phase 4Terminated
NCT02597829UCB PharmaCertolizumab Pegol

Does Clinical Response Correlate With Serum Certolizumab Levels?

Start: Nov 2015Est. completion: Oct 201820 patients
Phase 4Unknown

Top-down Infliximab Study in Kids With Crohn's Disease

Start: Apr 2015Est. completion: Jan 2024100 patients
Phase 4Completed

Cimzia Versus Mesalamine for Crohn's Recurrence

Start: Feb 2013Est. completion: Jun 201610 patients
Phase 4Terminated

Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)

Start: Jun 2010Est. completion: Dec 20100
Phase 4Withdrawn
NCT01030809AbbottTreatment Algorithm for Crohn's Disease

Trial of a Treatment Algorithm for the Management of Crohn's Disease

Start: Jan 2010Est. completion: Dec 20131,999 patients
Phase 4Completed
NCT01024647UCB Pharmacertolizumab pegol

Optimizing Cimzia in Crohn's Patients

Start: Dec 2009Est. completion: May 201350 patients
Phase 4Unknown

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Start: Dec 20080
Phase 4Withdrawn

Treatment With Infliximab in a Medical Setting (Study P05587)

Start: Nov 2008Est. completion: Jun 2010100 patients
Phase 4Terminated

Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)

Start: Jan 2008Est. completion: Nov 20087 patients
Phase 4Terminated

A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

Start: Oct 2007Est. completion: Oct 200948 patients
Phase 4Completed

A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease

Start: Oct 2005Est. completion: Feb 200650 patients
Phase 4Completed

Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)

Start: Aug 2005Est. completion: Aug 200510 patients
Phase 4Completed

A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)

Start: Oct 2004Est. completion: Jun 200742 patients
Phase 4Completed

Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)

Start: Oct 2004Est. completion: Feb 200744 patients
Phase 4Completed

Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)

Start: Jul 2003Est. completion: Apr 200419 patients
Phase 4Completed

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Start: Jul 2002Est. completion: Sep 20042,000 patients
Phase 4Completed

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Start: Mar 2026Est. completion: Dec 20291,182 patients
Phase 3Not Yet Recruiting

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Start: Jan 2026Est. completion: Mar 2034671 patients
Phase 3Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Start: Oct 2025Est. completion: May 2029980 patients
Phase 3Recruiting

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Start: Jul 2025Est. completion: Jul 2026606 patients
Phase 3Active Not Recruiting

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Start: Sep 2024Est. completion: May 20261,950 patients
Phase 3Active Not Recruiting

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Start: Nov 2023Est. completion: Nov 20251,108 patients
Phase 3Completed

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Start: Nov 2023Est. completion: Oct 2025693 patients
Phase 3Completed
NCT04701411TakedaDarvadstrocel

A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Start: Jun 2021Est. completion: May 20257 patients
Phase 3Terminated
NCT04643483UCB PharmaCertolizumab pegol

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Start: Jun 2021Est. completion: Apr 20260
Phase 3Withdrawn
NCT03961815AstraZenecaBrazikumab Induction Dose

Open-label Extension Study of Brazikumab in Crohn's Disease

Start: Jan 2020Est. completion: Sep 202318 patients
Phase 3Terminated

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

Start: Oct 2019Est. completion: Aug 2023396 patients
Phase 3Completed

Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease

Start: Mar 2019Est. completion: Feb 202322 patients
Phase 3Completed

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

Start: Aug 2018Est. completion: Oct 202030 patients
Phase 3Terminated
NCT03345849AbbVieUpadacitinib

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Start: Dec 2017Est. completion: Jan 2022526 patients
Phase 3Completed

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

Start: Sep 2017Est. completion: Jul 2023568 patients
Phase 3Completed
NCT03234907TakedaVedolizumab IV

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

Start: Aug 2017Est. completion: Aug 2020215 patients
Phase 3Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Start: Oct 2016Est. completion: Nov 20221,372 patients
Phase 3Completed

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Start: Aug 2015Est. completion: Dec 2017205 patients
Phase 3Completed

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Start: Oct 2014Est. completion: Oct 2017
Phase 3Terminated

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

Start: Aug 2014Est. completion: Aug 2017
Phase 3Terminated

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

Start: Oct 2013Est. completion: Mar 20160
Phase 3Withdrawn
NCT01817972UCB PharmaCertolizumab pegol

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

Start: Mar 2013Est. completion: Nov 201465 patients
Phase 3Unknown

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Start: Jul 2012Est. completion: Nov 2016278 patients
Phase 3Completed
NCT01514240AstraZenecaD9421-C capsule 3 mg

Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Start: Feb 2012Est. completion: Sep 2014123 patients
Phase 3Completed

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

Start: Feb 2011Est. completion: Jan 2017252 patients
Phase 3Completed

Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease

Start: Jun 2009Est. completion: Jun 2012
Phase 3Terminated

The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"

Start: Feb 2009Est. completion: Jul 20093 patients
Phase 3Terminated
NCT00358683UCB PharmaCertolizumab pegol

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

Start: Nov 20070
Phase 3Withdrawn
NCT00307931UCB PharmaCertolizumab pegol

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

Start: Apr 2007Est. completion: Aug 200816 patients
Phase 3Terminated
NCT00356408UCB PharmaCertolizumab pegol

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

Start: Jan 2007Est. completion: Feb 2010106 patients
Phase 3Completed

A Study of Abatacept in Patients With Active Crohn's Disease

Start: Dec 2006Est. completion: Nov 2009451 patients
Phase 3Terminated

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

43 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 16,596 patients
27 companies competing in this space